Cyclosporine Therapy – Liver Function Monitoring and Dosing Guidelines

Baseline Liver Assessment

• The British Association of Dermatologists requires a comprehensive baseline panel—including liver enzymes (alkaline phosphatase, bilirubin, transaminases), electrolytes, full blood count, fasting lipids, serum urate, and urinalysis—before starting cyclosporine. 1
• Hepatitis B and C serology should be obtained when risk factors are present, and HIV testing considered, as part of the pre‑treatment work‑up. 1

Contraindications in Patients with Liver Disease

• Severe hepatic dysfunction is a contraindication to cyclosporine because it markedly reduces drug clearance; dose reduction may be required if therapy is unavoidable. 4

Monitoring Schedule

• Initial phase (first 3 months): Liver function tests are performed every 2 weeks together with renal function assessment. 5
• Stabilisation phase (after 3 months): Once liver parameters are stable, monthly liver function testing is recommended. 5
• Long‑term therapy (>4 months): If stability persists, monitoring can be spaced to every 2–3 months. 7

Dosing Recommendations

• Dermatology guidelines advise a cyclosporine dose of 2.5–5 mg/kg per day, using the lowest effective dose and not exceeding 5 mg/kg. 4
• Short courses (up to 6 months) and intermittent regimens are preferred over continuous long‑term treatment to minimise toxicity. 4

Drug‑Interaction Considerations

• Cyclosporine is metabolised by CYP3A4; agents that induce CYP3A4 (e.g., barbiturates, carbamazepine, phenytoin, rifampicin, St John’s wort) can lower cyclosporine concentrations. 1
• CYP3A4 inhibitors (notably grapefruit juice) markedly increase cyclosporine levels and should be avoided. 1
• Because cyclosporine has a narrow therapeutic index, any concomitant medication should be cross‑checked against an up‑to‑date interaction reference. 2

Critical Monitoring Pitfalls

• Single, isolated liver test abnormalities are of limited clinical relevance; sustained changes over time should guide management decisions. 7

Integrated Monitoring Approach

• The British Association of Dermatologists recommends that liver function monitoring be performed alongside assessment of renal function, blood pressure, electrolytes (magnesium, potassium), lipids, and complete blood count. 1

All facts are derived from guideline‑level sources (British Association of Dermatologists, American Academy of Dermatology, FDA labeling) and reflect current consensus recommendations.